TP53 and neoplasm: Thus, pharmacological and/or genetic interventions that could restore or reactivate the p53 pathway by reducing the p53-MDM2 interaction, is a rational approach that was demonstrated in vitro as well as in vivo in xenograft models with significant tumor regression (15–17).